<DOC>
	<DOCNO>NCT02837146</DOCNO>
	<brief_summary>This study aim assess kinetics ultrasound ( US ) response DMARD-naive early rheumatoid arthritis ( RA ) patient treat tocilizumab ( TCZ ) methotrexate ( MTX ) .</brief_summary>
	<brief_title>Ultrasound Imaging Biomarker Early Response Tocilizumab Methotrexate Very Early Rheumatoid Arthritis</brief_title>
	<detailed_description>For rheumatic autoimmune disease , treatment two component : induction remission maintenance ( prevent relapse ) . After screen ( week -3 0 ) , patient enter 3 week run-in period glucocorticoid ( GC ) treatment allow . At week 0 , persistent synovitis confirm patient enter induction phase . During induction phase patient receive TCZ MTX week 0 week 24 . After week 24 , patient receive MTX . Ultrasound ( US ) increasingly use rheumatic disease , particular rheumatoid arthritis ( RA ) . The great resolution superficial musculoskeletal structure obtain use high frequency transducer high sensitivity colour Doppler ( CD ) power Doppler ( PD ) techniques allow detect synovial vascularisation , synovial hypertrophy ( SH ) joint effusion ( JE ) . This pilot US trial allow u explore hypothesis early US response may predictive later clinical response .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis RA fulfil 2010 EULAR/ACR ( European League Against Rheumatism/ American College Rheumatology classification criterion ) Disease duration longer 12 month time first swell joint longer 12 month time initial diagnosis Age : 1875 year Disease activity define disease activity score DAS28CRP &gt; 3.2 must meet : tender joint count ( TJC ) ≥4 swell joint count ( SJC ) ≥4 US SH PD synovitis score &gt; 1 least 2 joint ( MCP:25 PIP:25 CMC:25 wrist joint MTP:25 ankle joint ) US SH PD synovitis score ≥1 least 1 joint ( MCP:25 PIP:25 CMC:25 wrist joint ) Naïve DMARDs ( methotrexate , leflunomide , sulphasalazine ) naïve biologics biosimilars . History concomitant autoimmune disease lupus psoriatic arthritis Meeting diagnostic criterion rheumatic disease RA ( e.g . gout , Lyme disease , seronegative spondyloarthropathy include reactive arthritis , psoriatic arthritis , arthropathy inflammatory bowel disease ) Any previous treatment : 1 . Biologics : Etanercept , infliximab , certolizumab , golimumab , abatacept , adalimumab , anakinra , tocilizumab , tofacitinib , etc . 2 . Any celldepleting therapy , include investigational agent approve therapy , example CAMPATH , antiCD4 , antiCD5 , anti CD3 , antiCD19 antiCD20 3 . Intravenous gamma globulin , plasmapheresis Prosorba column within 6 month baseline . 4 . Alkylating agent chlorambucil , total lymphoid irradiation Previous MCP arthroplasty wrist arthrodesis . Participants undergone schedule undergo joint arthroplasty MCP joint recruit study provide eligibility criterion meet . Current liver disease require medication Current symptom severe progressive uncontrolled renal , hematologic , gastrointestinal , pulmonary , cardiac , neurologic cerebral disease whether related rheumatoid arthritis , would jeopardize inclusion protocol judge clinician History malignancy lymphoproliferative disease , within last 5 year , exception basal cell squamous cell carcinoma skin carcinoma situ cervix fully excised/cured evidence recurrence Concomitant diagnosis history diverticulitis , peptic ulcer disease , diverticulosis require antibiotic treatment chronic ulcerative low GI disease Crohn 's disease , ulcerative colitis symptomatic low GI condition might predispose perforation Evidence active latent bacterial , viral , fungal ( except fungal infection nail bed ) , mycobacterial opportunistic infection time potential enrolment Any major episode infection require hospitalisation treatment IV antibiotic within 4 week oral antibiotic within 2 week screen ' Herpes zoster cytomegalovirus infection resolve less 2 month inform consent sign Subjects risk tuberculosis ( TB ) exclude follow present : A history active TB within last 3 year , even treat Latent TB successfully treat ≥ 4 week Current clinical radiographic , laboratory evidence active TB Subjects receive live vaccine within 4 week anticipate first dose study medication . Live live attenuate vaccine give concurrently Subjects must agree take live attenuate vaccine ( include seasonal nasal flu vaccine , varicella vaccine shingle chickenpox , MMR MMRV , oral polio vaccine vaccine yellow fever , measles , mumps rubella ) thirty ( 30 ) day Screening Visit , throughout duration trial sixty ( 60 ) day follow subject 's last dose study drug Subjects positive test result hepatitis B surface antigen hepatitis C , HIV detect polymerase chain reaction immunoblot assay Subjects primary secondary immunodeficiency History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Major surgery within 8 week Patients lack peripheral venous access Pregnancy breastfeeding Females childbearing potential participate use reliable contraception Intraarticular steroid injection joint assess US le four week screen Anticipated noncompliance protocol Laboratory exclusion criterion Platelet count &lt; 100 x 109/l ( 100,000/mm3 ) Haemoglobin &lt; 85 g/l ( 8.5 g/dl ; 5.3 mmol/l ) ( &lt; 8.0 ) White Blood Cells &lt; 3.0 x 109/l ( 3000/mm3 ) &gt; 14,000/μl Absolute Neutrophil Count &lt; 2.0 x 109/l ( 2000/mm3 ) Absolute Lymphocyte Count &lt; 0.5 x 109/l ( 500/mm3 ) Positive Hepatitis BsAg , Hepatitis C antibody Serum creatinine &gt; 1.4 mg/dl ( 124 μmol/l ) female patient &gt; 1.6 mg/dl ( 141 μmol/l ) male patient . Patients serum creatinine value exceed limit may eligible GFR &gt; 30 Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5 time upper limit normal ( ULN ) Total Bilirubin &gt; ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>RA</keyword>
</DOC>